Bukwang Announces IR Conference Call for 2026 Q2 Earnings and R&D Update


  • Bukwang will hold a conference call on July 21, 2026 at 3 PM to present its 2026 Q2 business performance and R&D progress to institutional investors and analysts.
  • The IR event is hosted by the company itself and related materials will be posted on the company website on the same day.
  • The schedule is subject to change and this disclosure is simply an IR event notice with no capital changes or financial impact disclosed.
  • [AI Summary]This IR announcement is a routine schedule notice for periodic earnings disclosure without any capital raising or dilution. Therefore, short-term stock price volatility is likely limited, and investors should focus on the actual Q2 results and R&D pipeline progress.

KOSPI Filing Information


  • Corporate Briefing (IR) Holding (Notice Disclosure)
  • Company: BUKWANG PHARMACEUTICAL IND (003000)
  • Submission: BUKWANG PHARMACEUTICAL IND CO.,LTD
  • Under KRX KOSPI Market Division

  • Shares: 98,664,671
  • Price: 3,830 KRW
  • Market Cap: 377.9 B KRW